UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1113-13
Program Prior Authorization/Notification
Medication Votrient® (pazopanib)
P&T Approval Date 1/12/2010, 9/2010, 12/2010, 3/2011, 5/2012, 8/2012, 7/2013, 8/2014,
8/2015, 7/2016, 7/2017, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021,
11/2022, 11/2023, 11/2024
Effective Date 2/15/2025
1. Background:
Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of adults with advanced
renal cell carcinoma and advanced soft tissue sarcoma in patients who have received prior
chemotherapy. Additionally, the National Comprehensive Cancer Network (NCCN) recommends
use of Votrient in treatment of medullary, follicular, oncocytic, and papillary thyroid carcinomas;
ovarian cancer; additional soft tissue sarcomas, chondrosarcoma, uterine sarcoma, merkel cell
carcinoma, and gastrointestinal stromal tumors (GIST).
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of 19
years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or under
some circumstances. Some states also mandate usage of other Compendium references. Where such
mandates apply, they supersede language in the benefit document or in the notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Votrient will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Renal cell carcinoma (RCC)/Kidney cancer
1. Initial Authorization
a. Votrient will be approved based on one of the following criteria:
(1) Both of the following:
(a) Diagnosis of renal cell carcinoma (RCC)
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(b) One of the following:
i. Disease has relapsed
ii. Stage IV disease
iii. Disease is advanced
-OR-
(2) Diagnosis of von Hippel-Lindau (VHL)-associated renal cell carcinoma
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
C. Soft Tissue Sarcoma (STS)
1. Initial Authorization
a. Votrient will be approved based on the following criterion:
(1) Diagnosis of one of the following:
(a) Angiosarcoma
(b) Alveolar soft part sarcoma
(c) Pleomorphic rhabdomyosarcoma
(d) Retroperitoneal/Intra-abdominal disease that is unresectable, stage IV, or
postoperative treatment for residual disease
(e) Soft Tissue Sarcoma of the Extremity/Superficial Trunk or Head/Neck with
disease that is stage IV or recurrent and has disseminated metastases
(f) Solitary fibrous tumor/hemangiopericytoma
(g) Desmoid tumors (aggressive fibromatosis)
(h) Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous
Transformation
(i) Dedifferentiated Chordoma
(j) Epithelioid hemangioendothelioma
(k) Extraskeletal myxoid chondrosarcoma
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
© 2024 UnitedHealthcare Services, Inc.
2
Authorization will be issued for 12 months.
D. Thyroid Carcinoma
1. Initial Authorization
a. Votrient will be approved based on one of the following criteria:
(1) All of the following:
(a) Diagnosis of one of the following:
i. Follicular carcinoma
ii. Oncocytic carcinoma
iii. Papillary carcinoma
-AND-
(b) One of the following:
i. Unresectable locoregional recurrent disease
ii. Persistent disease
iii. Metastatic disease
-AND-
(c) One of the following:
i. Patient has symptomatic disease
ii. Patient has progressive disease
-AND-
(d) One of the following:
i. Disease is refractory to radioactive iodine treatment
ii. Distant metastatic disease not amenable to radioactive iodine
treatment
-OR-
(2) All of the following:
(a) Diagnosis of medullary carcinoma
-AND-
(b) One of the following:
© 2024 UnitedHealthcare Services, Inc.
3
i. Disease is progressive
ii. Disease is symptomatic with distant metastases
-AND-
(c) History of failure, contraindication, or intolerance to one of the
following:
i. Caprelsa (vandetanib)
ii. Cometriq (cabozantinib)
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
E. Uterine Sarcoma
1. Initial Authorization
a. Votrient will be approved based on both of the following criteria:
(1) Diagnosis of uterine sarcoma
-AND-
(2) One of the following:
(a) Disease is advanced
(b) Disease is recurrent/metastatic
(c) Disease is inoperable
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
F. Ovarian Cancer
1. Initial Authorization
© 2024 UnitedHealthcare Services, Inc.
4
a. Votrient will be approved based on all of the following criteria:
(1) Diagnosis of one of the following:
(a) Epithelial Ovarian Cancer
(b) Fallopian Tube Cancer
(c) Primary Peritoneal Cancer
-AND-
(2) One of the following:
(a) Disease is persistent
(b) Disease is recurrent
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
G. Chondrosarcoma
1. Initial Authorization
a. Votrient will be approved based on both of the following criteria:
(1) Diagnosis of chondrosarcoma
-AND-
(2) Disease is metastatic and widespread
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
H. Gastrointestinal Stromal Tumors (GIST)
© 2024 UnitedHealthcare Services, Inc.
5
1. Initial Authorization
a. Votrient will be approved based on all the following criteria:
(1) Diagnosis of GIST
-AND-
(2) Disease is unresectable, progressive, or metastatic
-AND-
(3) One of the following:
(a) Used as first-line therapy in SDH-deficient GIST
-OR-
(b) Used after progression on all of the following:
i. Gleevec (imatinib)
ii. Sutent (sunitinib)
iii. Stivarga (regorafenib)
iv. standard dose Qinlock (ripretinib)
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
I. Merkel Cell Carcinoma
1. Initial Authorization
a. Votrient will be approved based on all of the following criteria:
(1) Diagnosis of Merkel Cell Carcinoma
-AND-
(2) Disease is M1 disseminated
-AND-
(3) One of the following:
© 2024 UnitedHealthcare Services, Inc.
6
(a) Anti-PD-L1 or anti-PD-1 therapy is contraindicated
-OR-
(b) Disease has progressed on anti-PD-L1 or anti-PD-1 therapy
Authorization will be issued for 12 months.
2. Reauthorization
a. Votrient will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Votrient therapy
Authorization will be issued for 12 months.
J. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limit may be in place.
4. References:
1. Votrient [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
January 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org. Accessed October 9, 2024.
Program Prior Authorization/Notification - Votrient (pazopanib)
Change Control
8/2014 Annual review. Expanded disease description for RCC and reformatted
thyroid carcinoma. Updated Background and References.
8/2015 Annual review. Updated criteria for soft tissue cancer and thyroid
© 2024 UnitedHealthcare Services, Inc.
7
cancer. Added criteria for dermatofibrosarcoma protuberans and
ovarian cancer. Updated background and references.
7/2016 Annual review. Revised renal cell carcinoma and soft tissue sarcoma
criteria. Updated references.
7/2017 Annual review with no changes to coverage criteria. Updated
references.
11/2017 Updated criteria to align with NCCN recommendations for recurrent or
persistent ovarian cancer. Removed criteria for dermatofibrosarcoma
protuberans (DFSP) as no longer recommended by NCCN. Updated
reference.
11/2018 Annual review. Updated criteria to align with NCCN recommendations
for renal cell carcinoma. Removed “off-label” from NCCN
Compendium supported indications. Updated background and
references.
11/2019 Annual review. Updated criteria to align with NCCN recommendations
for soft tissue sarcomas, ovarian and uterine cancers. Added NCCN
recommended regimens criteria. Updated background and references.
11/2020 Annual review. Updated criteria to align with NCCN recommendations
for soft tissue sarcoma and thyroid carcinoma. Updated background and
references.
11/2021 Annual review. Updated criteria to align with NCCN recommendations
for soft tissue sarcoma. Added criteria for chondrosarcoma. Updated
background and references.
11/2022 Annual review. Added state mandate and updated references.
11/2023 Annual review. Moved and updated criteria for GIST into its own
section. Added Merkel Cell Carcinoma criteria per NCCN
recommendations. Updated Soft Tissue Sarcoma criteria to align with
NCCN. Updated Uterine Sarcoma criteria to align with NCCN.
Updated Hürthle cell to oncocytic to align with NCCN nomenclature.
Updated background to align with NCCN recommendations. Updated
reference.
11/2024 Annual review. Added epithelioid hemangioendothelioma and
extraskeletal myxoid chondrosarcoma to Soft Tissue Sarcoma criteria to
align with NCCN. Updated references.
© 2024 UnitedHealthcare Services, Inc.
8